Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.97 USD
Change Today +0.05 / 1.02%
Volume 5.8K
CAPR On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

capricor therapeutics inc (CAPR) Snapshot

Open
$4.88
Previous Close
$4.92
Day High
$4.97
Day Low
$4.82
52 Week High
03/19/15 - $10.68
52 Week Low
01/8/15 - $3.05
Market Cap
80.6M
Average Volume 10 Days
39.1K
EPS TTM
$-0.57
Shares Outstanding
16.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CAPRICOR THERAPEUTICS INC (CAPR)

Related News

No related news articles were found.

capricor therapeutics inc (CAPR) Related Businessweek News

No Related Businessweek News Found

capricor therapeutics inc (CAPR) Details

Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of novel therapeutics to prevent and treat cardiovascular diseases. Its lead product candidates include CAP-1002 and Cenderitide. The company was founded in 2005 and is based in Beverly Hills, California.

28 Employees
Last Reported Date: 03/30/15
Founded in 2005

capricor therapeutics inc (CAPR) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $232.9K
Executive Vice President, General Counsel and...
Total Annual Compensation: $243.8K
Vice President of Medical Affairs
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2014.

capricor therapeutics inc (CAPR) Key Developments

Capricor Therapeutics Appoints Houman Hemmati as Vice President of Medical and Clinical Development for New Therapies

Capricor Therapeutics, Inc. announced the appointment of Houman Hemmati, M.D., Ph.D. to the newly created position of Vice President of Medical and Clinical Development for New Therapies. In this role, Dr. Hemmati will work to drive promising new therapies such as Capricor's exosome platform into clinical development as he works closely with the R&D, manufacturing and product development teams. Prior to joining Capricor, Dr. Hemmati, an ophthalmologist, was Director of Clinical Development at Allergan, where responsibilities included early to late stage clinical trial development of high profile ophthalmic products such as Restasis-X as well as Allegan's androgen based ophthalmic treatment and AGN 199201 for presbyopia. Prior to his time at Allergan, he co-founded Avicenna Pharmaceuticals in Paris, France, to advance a technology based on cancer stem cell mutations he had discovered at Caltech.

Capricor Therapeutics Announces Receipt of Food and Drug Administration Clearance for the Phase I/II Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Related Cardiomyopathy

Capricor Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) have cleared its Investigational New Drug Application (IND) for the clinical development of CAP-1002 for the treatment of patients with Duchenne Muscular Dystrophy (DMD) related cardiomyopathy. CAP-1002 is Capricor's allogeneic, cardiosphere-derived cell (CDC) therapy already in clinical development for the treatment of heart disease. The HOPE-DUCHENNE trial is designed to enroll up to 24 patients in a randomized, multi-center study evaluating the safety and preliminary efficiency of CAP-1002. Patients will receive CAP-1002 in all three coronary arteries which will allow for it to be delivered to wide areas of the myocardium similar to that which was used earlier this year in the DYNAMIC trial. Previously, Capricor was granted orphan drug designation by the FDA for CAP-1002 used for the treatment of cardiomyopathy associated with DMD.

Capricor Therapeutics, Inc. Reports Unaudited Consolidated Earnings for the First Quarter Ended March 31, 2015

Capricor Therapeutics, Inc. reported unaudited consolidated earnings for the first quarter ended March 31, 2015. For the quarter, revenue was $1,041,667 against $1,041,667 a year ago. Loss from operation was $3,414,725 against $1,185,437 a year ago. Net loss was $3,476,131 or $0.23 per basic and diluted share against $1,210,611 or $0.10 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CAPR:US $4.97 USD +0.05

CAPR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CAPR.
View Industry Companies
 

Industry Analysis

CAPR

Industry Average

Valuation CAPR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.4x
Price/Book 11.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAPRICOR THERAPEUTICS INC, please visit www.capricor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.